<SEC-DOCUMENT>0001104659-23-072937.txt : 20230620
<SEC-HEADER>0001104659-23-072937.hdr.sgml : 20230620
<ACCEPTANCE-DATETIME>20230620164529
ACCESSION NUMBER:		0001104659-23-072937
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230620
FILED AS OF DATE:		20230620
DATE AS OF CHANGE:		20230620

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CureVac N.V.
		CENTRAL INDEX KEY:			0001809122
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39446
		FILM NUMBER:		231025868

	BUSINESS ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076
		BUSINESS PHONE:		49 7071 9883 0

	MAIL ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CureVac B.V.
		DATE OF NAME CHANGE:	20200410
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tm2319171d1_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>



<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -6.85pt"><B>REPORT OF FOREIGN PRIVATE
ISSUER</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -6.85pt"><B>PURSUANT TO RULE 13a-16
OR 15d-16 OF THE </B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -6.85pt"><B>SECURITIES EXCHANGE ACT
OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of June 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-39446</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CureVac N.V.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(<I>Exact Name of Registrant as Specified in Its
Charter</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Friedrich-Miescher-Strasse 15, 72076</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>T&uuml;bingen, Germany</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>+49 7071 9883 0</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Address of principal executive office)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Indicate by check mark whether the registrant files
or will file annual reports under cover of Form&nbsp;20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;20-F</FONT></TD>
    <TD STYLE="width: 5%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Wingdings">&#120;</FONT></P></TD>
    <TD STYLE="width: 10%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;40-F</FONT></TD>
    <TD STYLE="width: 30%">
<FONT STYLE="font-family: Wingdings">&#168;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 20, 2023, CureVac N.V. (the &#8220;Company&#8221;) issued a
press release announcing that the first participant was dosed with its investigational cancer vaccine CVGBM in a Phase 1 study. A first
data readout is expected in the second half of 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information included in this Form 6-K (including Exhibit 99.1,
but excluding the statements of the Company&#8217;s Chief Development Officer contained in Exhibit 99.1 hereto) is hereby incorporated
by reference into the Company&#8217;s Registration Statement on Form F-3 (File No. 333-259613).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">CUREVAC N.V.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="width: 50%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 3%; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 47%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/&nbsp;Alexander Zehnder</FONT></TD>
    </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt"><I>Chief Executive Officer</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: June 20, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT INDEX</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; width: 86px; text-align: center"><FONT STYLE="font-size: 10pt">EXHIBIT NO.</FONT></TD>
    <TD STYLE="width: 10px">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">DESCRIPTION</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: center"><A HREF="tm2319171d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="tm2319171d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">CureVac N.V. Press Release dated June 20, 2023.</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2319171d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><IMG SRC="tm2319171d1_ex99-1img01.jpg" ALT=""></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CureVac Doses First Patient in Phase 1 Study
of Cancer Vaccine Candidate for<BR>
Surgically Resected Glioblastoma</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">&nbsp;</TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Cancer
                                            vaccine candidate CVGBM utilizes single mRNA, encoding eight epitopes of tumor-associated
                                            antigens with demonstrated relevance in glioblastoma</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt">&nbsp;</TD><TD STYLE="width: 17.85pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Study
                                            designed to evaluate safety and immunogenicity in patients with glioblastoma after surgical
                                            resection and radiotherapy</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt">&nbsp;</TD><TD STYLE="width: 17.85pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First
                                            study to apply CureVac&rsquo;s second-generation mRNA backbone in oncology</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>T&Uuml;BINGEN, Germany / BOSTON, USA &ndash;
June 20, 2023 &ndash; </B>CureVac N.V. (Nasdaq: CVAC) (&ldquo;CureVac&rdquo;), a global biopharmaceutical company developing a new class
of transformative medicines based on messenger ribonucleic acid (&ldquo;mRNA&rdquo;), today announced that it has dosed the first patient
with its investigational cancer vaccine CVGBM in a Phase 1 study. CVGBM is based on CureVac&rsquo;s proprietary second-generation mRNA
backbone and features a single mRNA, encoding eight epitopes derived from known tumor-associated antigens with demonstrated relevance
in glioblastoma. A first data readout is expected in the second half of 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;We are excited to enter the execution
phase of our cancer vaccine development strategy with a study that is designed to establish proof-of-principle for our advanced second-generation
mRNA backbone in oncology,&rdquo; said Dr. Myriam Mendila, Chief Development Officer of CureVac. &ldquo;We will use the study data to
evaluate the ability of our second-generation mRNA backbone to raise strong tumor-directed immune responses and provide a firm foundation
to further advance our oncology pipeline based on our potent vaccine platform and an unparalleled framework for antigen discovery.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The open-label study evaluates the safety and
tolerability of CVGBM in patients with newly diagnosed and surgically resected MGMT-unmethylated glioblastoma or astrocytoma with a molecular
signature of glioblastoma. CVGBM is administered as a monotherapy after surgical resection and completion of radiotherapy with or without
chemotherapy. The study will consist of two parts, a dose-escalation part (Part A) and a dose-expansion part (Part B). In the initiated
Part A, patients will receive a total of seven intramuscular administrations of CVGBM at escalating doses in the range of 12 to 100 &micro;g
on days 1, 8, 15, 29, 43, 57, and 71. In patients without disease progression, vaccinations can continue beyond day 71 every 6 weeks
up until one year after the first CVGBM vaccination, disease progression or undue toxicity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About CVGBM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CVGBM is CureVac&rsquo;s first investigational
cancer vaccine based on its proprietary second-generation mRNA backbone designed for improved mRNA translation and increased as well
as extended protein expression. It encodes a single fusion protein comprising eight epitopes derived from tumor-associated antigens (TAA)
with relevance in glioblastoma, including HLA class I epitopes presented on HLA A201 and class II epitopes. The applied epitopes have
been previously shown to induce immune responses in glioblastoma patients when administered as peptide vaccines with adjuvants. CVGBM
applies unmodified mRNA and is formulated within lipid nanoparticles (LNPs). The Phase 1 proof-of-principle study of CVGBM is currently
being conducted in Germany, Belgium and the Netherlands.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-align: right; background-color: white"><B><IMG SRC="tm2319171d1_ex99-1img01.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-align: justify; background-color: white"><B>CureVac
Media and Investor Relations Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.35pt 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.35pt 0pt 0; text-align: justify; background-color: white">Dr. Sarah
Fakih, Vice President Corporate Communications and Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; text-align: justify; background-color: white">CureVac, T&uuml;bingen,
Germany</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; text-align: justify; background-color: white">T: +49 7071
9883-1298</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; text-align: justify; background-color: white">M: +49 160
90 496949</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>sarah.fakih@curevac.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About CureVac</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CureVac (Nasdaq: CVAC) is a global biopharmaceutical
company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, optimizing, and manufacturing
this versatile biological molecule for medical purposes. The principle of CureVac&rsquo;s proprietary technology is the use of optimized
mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. In July
2020, CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based
on CureVac&rsquo;s second-generation mRNA technology. This collaboration was later extended to the development of second-generation COVID-19
vaccine candidates, and modified mRNA vaccine technologies. Based on its proprietary technology, CureVac has built a deep clinical pipeline
across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac N.V. has
its headquarters in T&uuml;bingen, Germany, and has more than 1,100 employees across its sites in Germany, the Netherlands, Belgium,
Switzerland and the U.S. Further information can be found at <U>www.curevac.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statements CureVac</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains statements that constitute
 &ldquo;forward looking statements&rdquo; as that term is defined in the United States Private Securities Litigation Reform Act of 1995,
including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac N.V.
and/or its wholly owned subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac Corporate Services
GmbH, CureVac RNA Printer GmbH, CureVac Belgium SA and CureVac Netherlands B.V. (the &ldquo;company&rdquo;) regarding future events or
future results, in contrast with statements that reflect historical facts. Examples include statements regarding the completion, size
and terms of the proposed public offering. In some cases, you can identify such forward-looking statements by terminology such as &ldquo;anticipate,&rdquo;
 &ldquo;intend,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;plan,&rdquo; &ldquo;seek,&rdquo; &ldquo;project,&rdquo; or
 &ldquo;expect,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; &ldquo;could,&rdquo; &ldquo;potential,&rdquo; &ldquo;intend,&rdquo;
or &ldquo;should,&rdquo; the negative of these terms or similar expressions. Forward-looking statements are based on management&rsquo;s
current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are
not a guarantee of the company&rsquo;s performance, and you should not place undue reliance on such statements. Forward-looking statements
are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing
instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical
studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration
partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation,
regulations and governmental policies, pressures from increasing competition and consolidation in the company&rsquo;s industry, the effects
of the COVID-19 pandemic on the company&rsquo;s business and results of operations, ability to manage growth, reliance on key personnel,
reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the
effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned
not to place undue reliance on such statements. Many of these risks are outside of the company&rsquo;s control and could cause its actual
results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made
only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or
to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required
by law. For further information, please reference the company&rsquo;s reports and documents filed with the U.S. Securities and Exchange
Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at <U>www.sec.gov</U>.</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2319171d1_ex99-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2319171d1_ex99-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !" )8# 2(  A$! Q$!_\0
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9BB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
